David A. Siegel Onconova Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.67 - $1.01 $3,283 - $4,949	-4,900 Reduced 6.28%	73,066 $73,000
Q4 2023 Feb 14, 2024	SELL	$0.62 - $0.79 $10,461 - $13,329	-16,873 Reduced 17.79%	77,966 $58,000
Q3 2023 Nov 14, 2023	SELL	$0.71 - $1.15 $34,435 - $55,774	-48,500 Reduced 33.84%	94,839 $67,000
Q2 2023 Aug 14, 2023	BUY	$0.67 - $1.42 $78,122 - $165,572	116,600 Added 436.07%	143,339 $169,000
Q1 2023 May 15, 2023	SELL	$0.69 - $1.42 $16,145 - $33,228	-23,400 Reduced 46.67%	26,739 $19,000
Q4 2022 Feb 14, 2023	SELL	$0.63 - $0.97 $47,880 - $73,720	-76,000 Reduced 60.25%	50,139 $32,000
Q3 2022 Nov 14, 2022	SELL	$0.95 - $1.45 $50,134 - $76,520	-52,773 Reduced 29.5%	126,139 $111,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.9 $180,336 - $329,460	-173,400 Reduced 49.22%	178,912 $236,000
Q1 2022 May 16, 2022	BUY	$1.46 - $2.82 $83,220 - $160,740	57,000 Added 19.3%	352,312 $648,000
Q4 2021 Feb 14, 2022	BUY	$2.49 - $3.73 $735,326 - $1.1 Million	295,312 New	295,312 $753,000
Q3 2021 Nov 15, 2021	SELL	$3.81 - $6.76 $59,561 - $105,679	-15,633 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.28 - $16.2 $98,175 - $253,254	15,633 New	15,633 $108,000

249K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.